US2010267739A1PendingUtilityA1
Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
Individually held — no corporate assignee on recordPriority: Oct 13, 2000Filed: May 21, 2010Published: Oct 21, 2010
Est. expiryOct 13, 2020(expired)· nominal 20-yr term from priority
A61P 3/04A61P 43/00A61P 25/00A61P 25/22A61P 25/24A61P 25/20A61P 25/26A61P 25/04A61P 25/34A61P 25/18A61K 31/439A61P 23/00C07D 241/16C07D 213/61C07D 487/08C07D 401/04A61K 45/06A61K 31/551A61K 31/519A61K 31/455C07D 237/12C07D 403/04C07D 213/74A61K 31/46C07D 241/20C07D 237/20C07D 213/65A61K 31/00A61K 31/4439C07D 451/02
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as pharmaceutical compositions comprising these substances and chemical substances for use in such treatment.
Claims
exact text as granted — not AI-modified1 . 1-(5,6-Dibromo-3-pyridyl)-piperazine, or a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising a therapeutically effective amount of 1-(5,6-dibromo-3-pyridyl)-piperazine, or a pharmaceutically acceptable salt thereof, together with one or more adjuvants, excipients, carriers, and/or diluents.Join the waitlist — get patent alerts
Track US2010267739A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.